Table 4.
Functional Status Over 12 Months After Aortic Valve Replacement According to Delirium Status
| Time Since Surgery |
No Delirium | Delirium | Adjusted Differenceb (Delirium-No Delirium) Estimate (95% CI) |
||||
|---|---|---|---|---|---|---|---|
| N | Functional Score* Mean ± SD |
Change from Baseline† Estimate (95% CI) |
N | Functional Score* Mean ± SD |
Change from Baseline† Estimate (95% CI) |
||
| SAVR | |||||||
| Baseline | 38 | 18.8 ± 3.0 | Reference | 39 | 16.5 ± 3.3 | Reference | −1.8 (−3.1 to −0.4) |
| Month 1 | 35 | 15.7 ± 3.7 | −3.2 (−4.5 to −1.8) | 34 | 12.6 ± 4.6 | −4.4 (−5.7 to −3.0) | −3.0 (−4.9 to −1.0) |
| Month 3 | 32 | 17.8 ± 3.6 | −0.9 (−1.9 to 0.2) | 32 | 15.8 ± 3.9 | −1.1 (−2.2 to −0.1) | −2.1 (−3.9 to −0.3) |
| Month 6 | 30 | 19.0 ± 3.5 | 0.1 (−0.9 to 1.1) | 35 | 16.5 ± 3.7 | 0.0 (−1.0 to 1.0) | −1.8 (−3.5 to −0.2) |
| Month 9 | 32 | 18.9 ± 3.3 | 0.1 (−0.9 to 1.1) | 34 | 16.9 ± 4.0 | 0.3 (−0.7 to 1.3) | −1.5 (−3.2 to 0.2) |
| Month 12 | 32 | 18.7 ± 3.6 | −0.1 (−1.2 to 1.1) | 34 | 17.2 ± 3.7 | 0.6 (−0.5 to 1.8) | −1.1 (−2.7 to 0.6) |
| TAVR | |||||||
| Baseline | 82 | 14.6 ± 3.2 | Reference | 28 | 12.3 ± 5.0 | Reference | −2.3 (−3.9 to −0.6) |
| Month 1 | 77 | 13.8 ± 4.2 | −0.7 (−1.5 to 0.1) | 28 | 8.6 ± 5.7 | −3.6 (−5.0 to −2.3) | −5.2 (−7.2 to −3.2) |
| Month 3 | 72 | 14.7 ± 4.4 | 0.1 (−0.8 to 1.1) | 23 | 10.1 ± 6.1 | −2.7 (−4.4 to −1.1) | −5.1 (−7.4 to −2.9) |
| Month 6 | 66 | 14.2 ± 4.5 | −0.5 (−1.4 to 0.4) | 21 | 11.2 ± 5.9 | −2.0 (−3.6 to −0.4) | −3.7 (−6.0 to −1.5) |
| Month 9 | 63 | 14.8 ± 4.4 | −0.3 (−1.2 to 0.7) | 19 | 10.9 ± 6.1 | −2.8 (−4.6 to −1.1) | −4.8 (−7.2 to −2.5) |
| Month 12 | 63 | 14.5 ± 4.2 | −0.5 (−1.5 to 0.6) | 20 | 11.0 ± 6.2 | −2.3 (−4.1 to −0.5) | −4.1 (−6.4 to −1.8) |
Abbreviations: CI, confidence interval; NA, not applicable; SAVR, surgical aortic valve replacement; SD, standard deviation; TAVR, transcatheter aortic valve replacement
*
The functional status composite score ranges from 0 to 22, with higher scores indicating better function.
†
The change from baseline, group difference and their 95% confidence intervals were estimated from a linear mixed-effects regression model that adjusted for age, sex, and Charlson Comorbidity Index.